中国癌症杂志 ›› 2019, Vol. 29 ›› Issue (10): 780-787.doi: 10.19401/j.cnki.1007-3639.2019.10.004

• 论著 • 上一篇    下一篇

甲状腺乳头状癌中异常甲基化基因筛查

曹一鸣,朱永学   

  1. 复旦大学附属肿瘤医院头颈外科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2019-10-30 发布日期:2019-11-01
  • 通信作者: 朱永学 E-mail: zhuyongxue@sina.com

Screening of aberrant DNA methylation in papillary thyroid cancer

CAO Yiming, ZHU Yongxue   

  1. Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2019-10-30 Online:2019-11-01
  • Contact: ZHU Yongxue E-mail: zhuyongxue@sina.com

摘要: 背景与目的:DNA甲基化是一种重要表观遗传学改变,在肿瘤的发病、诊断、预后评估乃至治疗上都具有重要的临床意义。甲状腺癌是临床最常见的内分泌系统恶性肿瘤,目前国内外对甲状腺癌中DNA甲基化研究相对较少。筛查在甲状腺乳头状癌中存在异常甲基化的基因。方法:收集2014年1月—2014年6月在复旦大学附属肿瘤医院头颈外科行甲状腺癌根治手术的患者的甲状腺乳头状癌组织及癌旁的正常甲状腺组织88对。通过前期高通量甲基化DNA亲和纯化测序技术(Methylcap-Seq)初步建立甲状腺乳头状癌全基因组甲基化谱式。通过生物信息学手段及甲基化特异性PCR技术(methylation specific PCR,MSP)进行初筛和复筛。结果:通过生物信息学手段分析初步选取46个基因位点进行检测,最终发现HOXD10和FOXD2基因启动子区存在异常高甲基化改变。HOXD10基因在甲状腺癌组织中44.4%呈高甲基化,而在癌旁组织中仅20.5%(P<0.001);FOXD2基因在甲状腺癌组织中54.5%呈高甲基化,而在癌旁组织中仅38.6%(P<0.001)。其与甲状腺癌患者临床病理因素的多因素分析表明,HOXD10高甲基化改变与甲状腺癌病灶的多灶性相关(OR=3.71);FOXD2高甲基化改变与甲状腺癌病灶外侵相关(OR=5.91)。结论:HOXD10与FOXD2基因在甲状腺乳头状癌中存在高甲基化修饰。甲状腺乳头状癌的发生、发展可能受HOXD10与FOXD2基因的甲基化修饰调控。

Abstract: Background and purpose: DNA methylation is an important epigenetic modification. Evaluating the status of DNA methylation could be useful for diagnosis, prognostic evaluation and predicting the risk of cancer. Thyroid cancer is the most prevalent endocrine malignancy in humans. This study aimed to screen the aberrant methylated gene in papillary thyroid cancer. Methods: Human primary thyroid cancer tissues and adjacent non-tumor tissues were collected from patients initially surgically treated in the Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center. A total of 95 patients were enrolled in the study. In previous studies, we performed MethylCap-seq and made up a database of genome-wide profiling of methylation in papillary thyroid cancer. Using bioinformatics tools and methylation specific PCR, we screened out the aberrant methylated genes. Results: Using bioinformatics tools, we screened 46 suspicious sites for further research. HOXD10 and FOXD2 were found to have aberrant hypermethylation in their promoter regions. The gene HOXD10 was hypermethylated in 44.4% of cancer tissues and 20.5% of adjacent tissues (P<0.001). The gene FOXD2 was hypermethylated in 54.5% of cancer tissues and 38.6% of adjacent tissues (P<0.001). The hypermethylation of HOXD10 gene was associated with tumor multifocality (OR=3.71), and the hypermethylation of FOXD2 gene was associated with tumor invasion (OR=5.91). Conclusion: The promoters of HOXD10 and FOXD2 may be hypermethylated in papillary thyroid cancer. And the epigenetic modification of HOXD10 and FOXD2 may play a role in tumorigenesis of thyroid cancer.